Last reviewed · How we verify
Recombinant Human Lactoferrin
At a glance
| Generic name | Recombinant Human Lactoferrin |
|---|---|
| Sponsor | Agennix |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effects of Lactoferrin at Two Doses vs. Active Control on Markers of Immune Function (NA)
- Effects of rhLactoferrin on Chronic Inflammation in the Elderly (PHASE2)
- The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia (PHASE1)
- Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (PHASE1)
- Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer (PHASE3)
- Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer (PHASE3)
- Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants (PHASE1, PHASE2)
- Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Human Lactoferrin CI brief — competitive landscape report
- Recombinant Human Lactoferrin updates RSS · CI watch RSS
- Agennix portfolio CI